Characterization of the Class I-Restricted gp100 Melanoma Peptide-stimulated Primary Immune Response in Tumor-Free Vaccine-draining Lymph Nodes and Peripheral Blood
- 1 April 2009
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (7) , 2541-2551
Abstract
Purpose: The aim of this study was to characterize the primary gp100209-2M-specific T-cell response in vaccine-draining, metastases-free lymph nodes and peripheral blood of peptide-vaccinated stage I to III melanoma patients. Experimental Design: After two or three gp100209-2M vaccinations, sentinel lymph nodes that drained both the primary tumor and adjacent vaccine sites were excised concomitant with wide excision of the tumor. Comparative 7-color flow cytometry phenotype analysis was done on gp100 tetramer-positive CD8+ T cells from sentinel lymph nodes, closely proximate time-related peripheral blood mononuclear cells (PBMC) collected 2 to 4 weeks after sentinel lymph node excision, and on PBMC collected 6 months later after 7 or 11 more immunizations. Lymph node and peripheral blood T cells were tested for proliferative response, functional avidity, and tumor cell–induced CD107 mobilization. Results: The frequencies of gp100-specific CD8+ T cells from time-related PBMC and sentinel lymph nodes were comparable and were similar to those reported for virus-specific memory T cells. Their respective in vitro proliferation responses were also equivalent but statistically higher than proliferation responses of peripheral blood T cells collected after completion of the entire vaccine regimen. By contrast, functional avidity and CD107 responses were significantly higher in circulating T cells. Sentinel lymph node–derived, gp100-specific CD8+ T cells predominantly expressed central and effector memory phenotype signatures, whereas there were higher frequencies of effector T cells in the peripheral blood. Conclusion: Priming immunization with gp100209-2M without coadministration of CD4+ helper T cell–restricted antigens induced the effective expansion of peptide-specific central and effector memory CD8+ T cells with high proliferation potential in vaccine-draining lymph nodes of stage I to III melanoma patients. Lymph node memory T cells gave rise to circulating gp100-specific effector T cells exhibiting increased functional maturation.Keywords
This publication has 48 references indexed in Scilit:
- Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine With Multiple Peptides From MAGE and Melanocytic Differentiation AntigensJournal of Clinical Oncology, 2008
- Phenotype and Functional Characterization of Long-term gp100-Specific Memory CD8+ T Cells in Disease-Free Melanoma Patients Before and After Boosting ImmunizationClinical Cancer Research, 2008
- Immunobiology of the sentinel lymph node and its potential role for antitumour immunityThe Lancet Oncology, 2006
- CD8+ T‐cell memory in tumor immunology and immunotherapyImmunological Reviews, 2006
- Hyperlog—A flexible log‐like transform for negative, zero, and positive valued dataCytometry Part A, 2005
- Seventeen-colour flow cytometry: unravelling the immune systemNature Reviews Immunology, 2004
- New approaches to fluorescence compensation and visualization of FACS dataClinical Immunology, 2004
- Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokinesBlood, 2003
- Lineage relationship and protective immunity of memory CD8 T cell subsetsNature Immunology, 2003
- Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patientsInternational Journal of Cancer, 2001